Hermens Daniel F, Naismith Sharon L, Chitty Kate M, Lee Rico S C, Tickell Ashleigh, Duffy Shantel L, Paquola Casey, White Django, Hickie Ian B, Lagopoulos Jim
Clinical Research Unit, Brain and Mind Research Institute, University of Sydney, Australia.
Clinical Research Unit, Brain and Mind Research Institute, University of Sydney, Australia.
Eur Neuropsychopharmacol. 2015 Jun;25(6):836-45. doi: 10.1016/j.euroneuro.2015.02.009. Epub 2015 Mar 5.
While numerous studies have employed magnetic resonance spectroscopy (MRS) to determine in vivo neurometabolite levels associated with mood disorders the findings in both unipolar depression and bipolar disorder have been mixed. Data-driven studies may shed new light on this literature by identifying distinct subgroups of patients who may benefit from different treatment strategies. The objective of the present study was to utilize hierarchical cluster analysis in order to generate new hypotheses with respect to neurometabolic profiling of mood disorder. Participants were 165 young persons (18-30 yrs) with a mood disorder and 40 healthy controls. Neurometabolite levels were recorded via proton-MRS ((1)H MRS). The ratios (relative to creatine) of glutamate (GLU), N-acetyl aspartate (NAA) and myo-inositol (MI) measured within the hippocampus. Self-reported and clinician rated symptoms as well as cognition were also measured. The unipolar depression (N=90) and bipolar disorder (N=75) groups did not significantly differ (from each other or controls) in their levels of GLU, NAA or MI. Cluster analyses derived four subgroups of patients who were distinguished by all three metabolites. There was a pattern of positive association between NAA and GLU, whereby clusters were abnormally increased (clusters 1, 2) or normal (cluster 4) or abnormally decreased (cluster 3) in these neurometabolites. These findings suggest that there are neurometabolic abnormalities in subgroups of young people with mood disorder, which may occur despite diagnostic similarities. Such evidence highlights that the underlying neurobiology of mood disorder is complex and MRS may have unique utility in delineating underlying neurobiology and targeting treatment strategies.
尽管众多研究已采用磁共振波谱(MRS)来测定与情绪障碍相关的体内神经代谢物水平,但单相抑郁症和双相情感障碍的研究结果却喜忧参半。数据驱动的研究可能通过识别可能从不同治疗策略中受益的不同患者亚组,为该文献提供新的线索。本研究的目的是利用层次聚类分析,以生成关于情绪障碍神经代谢谱的新假设。参与者为165名患有情绪障碍的年轻人(18 - 30岁)和40名健康对照者。通过质子磁共振波谱(¹H MRS)记录神经代谢物水平。测量海马体内谷氨酸(GLU)、N - 乙酰天门冬氨酸(NAA)和肌醇(MI)与肌酸的比值。还测量了自我报告和临床医生评定的症状以及认知情况。单相抑郁症组(N = 90)和双相情感障碍组(N = 75)在GLU、NAA或MI水平上(彼此之间或与对照组相比)无显著差异。聚类分析得出四个患者亚组,这些亚组由所有三种代谢物区分开来。NAA和GLU之间存在正相关模式,即这些神经代谢物在各亚组中异常升高(第1、2组)、正常(第4组)或异常降低(第3组)。这些发现表明,患有情绪障碍的年轻人群体亚组中存在神经代谢异常,尽管诊断上有相似之处,但这种异常仍可能发生。这些证据突出表明,情绪障碍的潜在神经生物学机制很复杂,而MRS在描绘潜在神经生物学机制和确定治疗策略方面可能具有独特的效用。